Eloxx Pharmaceuticals Aktie - ELOX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,82

Gebot

3,60

Fragen

3,75

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

12,008M

Handelsende

3,82

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

3.143.390

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

-11,47

Erlöse

Nettogewinn

-36,07M

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small... Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.eloxxpharma.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations...

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ELOX - Frequently Asked Questions (FAQ)

What is the current Eloxx Pharmaceuticals share price?

The current share price of Eloxx Pharmaceuticals is US$ 3,82

How many Eloxx Pharmaceuticals shares are in issue?

Eloxx Pharmaceuticals has 3.143.390 shares in issue

What is the market cap of Eloxx Pharmaceuticals?

The market capitalisation of Eloxx Pharmaceuticals is USD 12,01M

What is the 1 year trading range for Eloxx Pharmaceuticals share price?

Eloxx Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals reports financial results in USD

What is the latest annual profit for Eloxx Pharmaceuticals?

The latest annual profit of Eloxx Pharmaceuticals is USD -36,07M

What is the registered address of Eloxx Pharmaceuticals?

The registered address for Eloxx Pharmaceuticals is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Eloxx Pharmaceuticals website address?

The website address for Eloxx Pharmaceuticals is www.eloxxpharma.com

Which industry sector does Eloxx Pharmaceuticals operate in?

Eloxx Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
BAOSBaosheng Media Group Holdings Ltd	US$ 7,10 (310,40%)	58,74M
HOURHour Loop Inc	US$ 4,40 (207,69%)	97,42M
GTIGraphjet Technology	US$ 0,61 (168,72%)	265,48M
CREVCarbon Revolution Public Ltd	US$ 9,16 (135,48%)	26,95M
AVGRAvinger Inc	US$ 1,45 (125,72%)	107,53M
SLGLSol Gel Technologies Ltd	US$ 0,9798 (-40,62%)	3,07M
DRCTDirect Digital Holdings Inc	US$ 3,71 (-32,55%)	23,82M
CHEKCheck Cap Ltd	US$ 1,55 (-31,11%)	3,49M
SYTASiyata Mobile Inc	US$ 0,5178 (-30,83%)	2,63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF	US$ 15,47 (-30,38%)	147,98k
SVMHSRIVARU Holding Ltd	US$ 0,0338 (20,71%)	280,27M
GTIGraphjet Technology	US$ 0,61 (168,72%)	265,48M
LITMSnow Lake Resources Ltd	US$ 0,5849 (52,84%)	181,22M
LCIDLucid Group Inc	US$ 3,20 (3,23%)	108,75M
RGTIRigetti Computing Inc	US$ 11,35 (3,56%)	108,38M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eloxx Pharmaceuticals Inc (ELOX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Eloxx Pharmaceuticals Inc

ELOX Neueste Nachrichten

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Form 8-K - Current report

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Form 8-K - Current report

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

ELOX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eloxx Pharmaceuticals Inc (ELOX) Börsenkurse

Eloxx Pharmaceuticals Inc (ELOX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Eloxx Pharmaceuticals Inc

ELOX Neueste Nachrichten

ELOX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS